1. ERBB receptors and cancer: the complexity of targeted inhibitors;Hynes;Nat. Rev. Cancer,2005
2. The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells;Moasser;Cancer Res.,2001
3. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling;She;Clin. Cancer Res.,2003
4. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3;Sergina;Nature,2007
5. Untangling the ErbB signalling network;Yarden;Nat. Rev. Mol. Cell. Biol.,2001